Krege, John H. http://orcid.org/0000-0003-3914-0951
Lipton, Richard B.
Baygani, Simin K.
Komori, Mika
Ryan, Sinéad M.
Vincent, Maurice
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
https://doi.org/10.1007/s40122-022-00388-8
Documents that mention this clinical trial
Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
https://doi.org/10.1007/s40122-022-00388-8
Targeting the Pancreatic α-Cell to Prevent Hypoglycemia in Type 1 Diabetes
https://doi.org/10.2337/dbi20-0048
Documents that mention this clinical trial
Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
https://doi.org/10.1007/s12325-022-02291-2
Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
https://doi.org/10.1007/s40122-022-00388-8
Documents that mention this clinical trial
Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
https://doi.org/10.1007/s40122-022-00388-8
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
https://doi.org/10.1007/s40120-022-00403-2
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 18 February 2022
Accepted: 4 April 2022
First Online: 26 April 2022